An overview of the heparin-induced thrombocytopenia syndrome

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 3, 2004, Pages 273-283

  Warkentin, Theodore E ^a,b  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Endothelium; Heparin induced thrombocytopenia; Monocyte; Platelet activation; Thrombin generation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; COUMARIN; EPTIFIBATIDE; HEPARAN SULFATE; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; IODINATED CONTRAST MEDIUM; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEOGLYCAN; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; TIROFIBAN; WARFARIN;

ARTERY THROMBOSIS; AUTOIMMUNITY; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL HETEROGENEITY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; ENDOTHELIUM CELL; GANGRENE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; IN VITRO STUDY; IN VIVO STUDY; INTRAVASCULAR CATHETER; LEUKOCYTE; LIMB AMPUTATION; LIMB BLOOD VESSEL; MONOCYTE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; VASCULAR ENDOTHELIUM;

ANTIBODIES; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; COUMARINS; HEPARIN; HEPARITIN SULFATE; HUMANS; IMMUNOGLOBULIN G; MODELS, BIOLOGICAL; MONOCYTES; PHENOTYPE; PLATELET ACTIVATION; PLATELET FACTOR 4; THROMBIN; THROMBOCYTOPENIA; THROMBOSIS;

EID: 3843135119     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831039     Document Type: Review

References (74)

1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7
2. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003;101:31-37
3. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-555
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
5. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96: 1703-1708
6. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524
7. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 3rd ed. New York: Marcel Dekker; 2004:107-148
8. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003;121:786-792
9. Liu JC, Lewis BE, Steen LH, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 2002;89:979-981
10. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812
11. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851
12. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003;110:73-82
13. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699
14. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/ anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10:249-258
15. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets 1999;10:319-326
16. Hughes M, Hayward CPM, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000;96:188-194
17. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994;83:1535-1541
18. Denomme GA. The platelet Fc receptor in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 2nd ed. New York Marcel Dekker; 2004:223-250
19. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-96
20. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 1998;91:916-922
21. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998;92:3250-3259
22. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002;99:1230-1236
23. Marcum JA, Rosenberg RD. The biochemistry, cell biology, and pathophysiology of anticoagulantly active heparin-like molecules of the vessel wall. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. Boca Raton, FL: CRC Press; 1989:275-274
24. Silver D, Kapsch DN, Tsoi EKM. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Ann Surg 1983; 198:301-306
25. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88
26. Greinacher A, Pötzsch B, Amiral J, Dummel B, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251
27. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589
28. Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326-331
29. Rosenberg RD, Aird WC. Mechanisms of disease: vascular-bed - specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-1564
30. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-3777
31. Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost 2000;26:463-478
32. Sedmak DD, Davis DH, Singh U, van de Winkel JGJ, Anderson CL. Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am J Pathol 1991;138:175-181
33. Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol 1993;71:571-581
34. Gröger M, Sarmay G, Fiebiger E, Wolff K, Petzelbauer P. Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J Immunol 1996;156:1549-1556
35. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-228
36. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996;92:494-497
37. Warkentin TE. Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis. Thromb Haemost 1997;77(suppl):562
38. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/ heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14:121-129
39. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001;98:1252-1254
40. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-3302
41. Fareed J, Walenga JM, Hoppensteadt DA, et al. Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clin Appl Thromb Hemost 1999;5(suppl 1):S38-S44
42. Fareed J, Walenga JM, Hoppensteadt DA, et al. Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 1999;25(suppl 1):37-42
43. Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:1090-1096
44. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998;102:136-144
45. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999;82:794-800
46. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958;76:219-227
47. Kwaan HC, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(suppl 1):23-27
48. Amiral J, Pouplard C, Vissac AM, Walenga JM, Jeske W, Gruel Y. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000;109:336-341
49. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
50. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003;348:1067-1069
51. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136:210-215
52. Balduini CL, Noris P, Bertolino G, Previtali M. Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infarction. Thromb Haemost 1993;69:522-523
53. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813
54. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75-83
55. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076
56. Chang JC, Lee D, Gross HM. Acute thrombocytopenia after IV administration of a radiographic contrast medium. AJR Am J Roentgenol 1989;152:947-949
57. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302
58. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863
59. Jang I-K, Lewis BE, Matthai WH, Kleiman NS. Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;91(suppl):68A
60. Lewis B, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F; ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184
61. Mahaffey KW, Lewis BE, Wildermann NM, et al. ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003;15: 611-616
62. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-2131
63. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002;126:1415-1423
64. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148-157
65. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003;101:3049-3051
66. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986;4:522-528
67. Warkentin TE, Aird WC, Rand J. Platelet-endothelial interaction: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am Soc Hematol Edu Program) 2003:497-519
68. Lo GK, Warkentin TE. Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: the "4 T's. Blood 2003; 102(suppl 1):535a
69. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507
70. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106: 629-635
71. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843
72. Lubenow N, Eichler P, Leitz T, Greinacher A. Meta-analysis of three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. Blood 2002;100(suppl 1):501a-502a
73. Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002;71:50-52
74. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;164:66-70